Sucampo Pharmaceuticals (NASDAQ:SCMP) was downgraded by equities researchers at BidaskClub from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Wednesday, February 14th.
A number of other research firms have also recently weighed in on SCMP. ValuEngine raised Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, December 7th. Maxim Group restated a “buy” rating and issued a $23.00 target price on shares of Sucampo Pharmaceuticals in a research note on Thursday, November 2nd. Instinet began coverage on Sucampo Pharmaceuticals in a research note on Tuesday, December 19th. They issued a “buy” rating and a $43.00 target price for the company. Mizuho lifted their price objective on Sucampo Pharmaceuticals from $12.00 to $14.00 and gave the company a “neutral” rating in a research note on Friday, December 8th. Finally, Nomura reiterated a “neutral” rating and set a $18.00 price objective on shares of Sucampo Pharmaceuticals in a research note on Friday, January 26th. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $20.25.
Sucampo Pharmaceuticals (SCMP) remained flat at $$18.00 during trading on Wednesday. The company’s stock had a trading volume of 956,100 shares, compared to its average volume of 2,557,332. The company has a current ratio of 5.11, a quick ratio of 4.46 and a debt-to-equity ratio of 7.37. The stock has a market cap of $839.46, a price-to-earnings ratio of -5.37, a PEG ratio of 5.06 and a beta of 1.38. Sucampo Pharmaceuticals has a fifty-two week low of $9.30 and a fifty-two week high of $18.75.
In related news, insider Peter A. Kiener sold 50,000 shares of Sucampo Pharmaceuticals stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $16.50, for a total value of $825,000.00. Following the completion of the transaction, the insider now owns 52,023 shares in the company, valued at approximately $858,379.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 4.13% of the stock is owned by insiders.
A number of hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC boosted its holdings in Sucampo Pharmaceuticals by 49.9% in the 4th quarter. Renaissance Technologies LLC now owns 1,957,600 shares of the biopharmaceutical company’s stock worth $35,139,000 after buying an additional 651,900 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Sucampo Pharmaceuticals during the 3rd quarter worth approximately $21,989,000. Vanguard Group Inc. boosted its holdings in shares of Sucampo Pharmaceuticals by 13.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,646,348 shares of the biopharmaceutical company’s stock worth $17,287,000 after purchasing an additional 189,561 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Sucampo Pharmaceuticals by 1.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,570,172 shares of the biopharmaceutical company’s stock worth $16,487,000 after purchasing an additional 15,528 shares during the last quarter. Finally, Alpine Associates Management Inc. acquired a new position in shares of Sucampo Pharmaceuticals during the 4th quarter worth approximately $26,845,000. Institutional investors own 67.09% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Sucampo Pharmaceuticals (SCMP) Downgraded by BidaskClub” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/22/sucampo-pharmaceuticals-scmp-lowered-to-buy-at-bidaskclub.html.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.